ARTICLE | Product Development
Liraglutide's Big(ger) Picture
Why Novo thinks 3mg liraglutide will clear FDA hurdles for obesity in diabetes
April 8, 2013 7:00 AM UTC
Novo Nordisk A/S is confident that 3 mg liraglutide will clear FDA's efficacy hurdles for obesity therapies even though that dose hit the less preferred of the agency's two obesity benchmarks in a Phase IIIa trial in obese diabetics.
The company also expects aggregate data from all obesity and diabetes trials of liraglutide will obviate the need for a long-term cardiovascular outcomes study of the 3 mg dose...